Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Date:1/29/2008

chaperone compounds for lysosomal storage disorders. Shire licensed the rights to commercialize these products outside of the United States and Amicus retained all rights to commercialize these products in the United States.

Program Advancements:

Fabry Disease:

In December 2007, Amicus announced positive results from its Phase 2 clinical trials of Amigal(TM) for Fabry disease. 26 patients completed the study, which was designed to evaluate safety and preliminary efficacy of multiple doses and regimens of Amigal in a broad range of Fabry disease patients. A majority of patients in these studies discontinued their enzyme replacement therapy (ERT) prior to enrollment in the Amigal protocols.
Key findings include the following:

-- Amigal was generally safe and well-tolerated at all doses evaluated and

no drug-related serious adverse events were reported

-- Amigal increased the level of the enzyme deficient in Fabry patients in

24 of 26 study subjects

-- Amigal was shown to reduce the accumulated substrate in a majority of

study subjects

-- Renal and cardiac function results were encouraging, including those

seen in patients treated for nearly two years

-- Responses in patients with different Fabry mutations were consistent

with the results of in vitro testing, thus confirming the ability to

use pharmacogenetics to select likely responders for future studies

-- 23 patients have elected to continue Amigal treatment in an extension

protocol

The Phase 2 Amigal study results will be presented to the scientific and medical community at the American College of Medical Genetics (ACMG) Annual Meeting on March 12-16, 2008, in Phoenix, Arizona.

Gaucher Disease:

Amicus also recently announced positive interim results from its first Phase 2 clinical trial for Gaucher disease in patients who switched from enzyme replacement therapy (
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
2. Amicus Therapeutics to Host R&D Day
3. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
4. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
5. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
6. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
7. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
9. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
10. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
11. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... May 06, 2015 The Remedy ... growth strategy for the specialty pharmacy industry, will be ... 2015 Armada Specialty Pharmacy Summit. The Summit will be ... Las Vegas and is the largest annual gathering for ... in attendance, from pharmacy providers, pharma/biotech manufacturers, and payers, ...
(Date:5/5/2015)... 2015  23andMe, Inc., the leading personal genetics company, ... Study in collaboration with Pfizer Inc. The companies ... more commonly known as lupus, into the study to ... is also in collaboration with the Lupus Research Institute, ... Approximately 1.5 million people in the U.S. ...
(Date:5/5/2015)... 5, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... continue trading on OTCQB  Marketplace, the market for ... allows for a continuous public market for trading ... real-time quotes and market information on us through ... Marketplace includes U.S. and international companies in venture ...
(Date:5/5/2015)... May 5, 2015  A group of biotechnology executives ... Coma Research Institute, a non-profit organization dedicated to providing ... suffering from disorders of consciousness.  ...   ... in which no voluntary actions can be initiated by ...
Breaking Biology Technology:The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5
... March 13 Proteon Therapeutics, Inc.,( http://www.proteontherapeutics.com ... first-in-class pharmaceuticals to address the,medical needs of ... appointed,Gregory D. Phelps, a seasoned biopharmaceutical executive, ... brings more than 30 years of executive,leadership ...
... Lead Candidate HspE7 into Phase 2 Clinical Trial in ... ... Nventa Biopharmaceuticals,Corporation announced today financial results for the year ended December,31, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO ), During 2007, the Company achieved the ...
... FAIRFIELD, New Jersey, March 13, "The new Stonegate ... as the only biopharma company that,manufactures peptides by ... systems to administer the peptides. Since the launch ... has,captured a near dominant 49% market share of ...
Cached Biology Technology:Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 2Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 3Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 4Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 5Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 6Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results 7Stonegate Report About Unigene Laboratories Inc. 2Stonegate Report About Unigene Laboratories Inc. 3Stonegate Report About Unigene Laboratories Inc. 4Stonegate Report About Unigene Laboratories Inc. 5Stonegate Report About Unigene Laboratories Inc. 6Stonegate Report About Unigene Laboratories Inc. 7Stonegate Report About Unigene Laboratories Inc. 8Stonegate Report About Unigene Laboratories Inc. 9Stonegate Report About Unigene Laboratories Inc. 10
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... research published in Biochemical and Biophysical Research Communications ... can detect new, previously unknown viruses. The technique offers ... doctors have not identified a particular virus as the ... the new approach, scientists use blood serum as a ...
... SAN FRANCISCO-- Vitamin D supplementation may help delay early onset ... results were presented Monday at The Endocrine Society,s 95th Annual ... between the ages of 10 and 14. Boys undergo these ... Precocious puberty is diagnosed in girls when sexual development begins ...
... Bethesda, MD (June 17, 2013) The AGA Research ... advancing in the future of gastroenterology with the 2013 ... Pharma Student Abstract Prizes. "In its third year, ... researchers who are embarking on promising careers in basic ...
Cached Biology News:Saint Louis University researchers discover a way to detect new viruses 2Saint Louis University researchers discover a way to detect new viruses 3Vitamin D supplementation may delay precocious puberty in girls 2Horizon Pharma Abstract Prizes recognize promising fellows and students 2
... Doublestain System is a high-sensitivity peroxidase ... The kit is intended for use ... of two different antigens within the ... suitably diluted rabbit and mouse primary ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
... VAMP-2 (Vesicle-Associated Membrane Protein 2, ... not share homology with any ... It is expected that the ... human, Macaca multata and bovine ...
... locus encodes two unrelated proteins both of ... the cell cycle in a p53-dependent manner. ... rapid degradation of mdm2 proteinrequired for mdm2 ... This interaction is mediated by the ...
Biology Products: